Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Cancer Statistics, 2021

Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2021 · 17.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.8K citations · Full text

Medicine, Oncology, Pharmacology +13

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.7K citations

Medicine, Oncology, Pharmacology +13

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma, Robert Olson, Stephen Harrow et al. · The Lancet · 2019 · 1.9K citations

Medicine, Oncology, Radiation Oncology +15